{"id":"rabeprazole-40-mg","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Atazanavir","action":"Avoid","effect":"Decreased absorption of atazanavir"},{"drug":"Clopidogrel","action":"Monitor","effect":"Decreased clopidogrel effectiveness"},{"drug":"Ketoconazole","action":"Monitor","effect":"Increased rabeprazole levels"},{"drug":"Erythromycin","action":"Monitor","effect":"Increased rabeprazole levels"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Digoxin","action":"Monitor","effect":"Increased digoxin levels"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased methotrexate levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Amoxicillin","action":"Monitor","effect":"Decreased amoxicillin effectiveness"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Iron","action":"Avoid","effect":"Decreased iron absorption"},{"drug":"Calcium","action":"Avoid","effect":"Decreased calcium absorption"},{"drug":"Vitamin B12","action":"Avoid","effect":"Decreased vitamin B12 absorption"},{"drug":"Cisapride","action":"Avoid","effect":"Increased risk of QT prolongation"},{"drug":"Fosamprenavir","action":"Avoid","effect":"Decreased absorption of fosamprenavir"},{"drug":"Rifampicin","action":"Monitor","effect":"Decreased rabeprazole levels"},{"drug":"Sulfonylureas","action":"Monitor","effect":"Increased risk of hypoglycemia"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"},{"drug":"Sirolimus","action":"Monitor","effect":"Decreased sirolimus levels"},{"drug":"Cyclosporine","action":"Monitor","effect":"Decreased cyclosporine levels"},{"drug":"Tacrolimus","action":"Monitor","effect":"Decreased tacrolimus levels"},{"drug":"Mycophenolate","action":"Monitor","effect":"Decreased mycophenolate levels"}],"commonSideEffects":[],"contraindications":["Patients with a history of hypersensitivity to rabeprazole (4).","PPIs, including rabeprazole sodium delayed-release tablets, are contraindicated in patients receiving rilpivirine-containing products (4,7).","Refer to the Contraindications section of the prescribing information for clarithromycin and amoxicillin, when administered in combination with rabeprazole sodium delayed-release tablets (4).","Gastric Malignancy: In adults, symptomatic response to therapy with rabeprazole does not preclude the presence of gastric malignancy. Consider additional follow-up and diagnostic testing (5.1).","Use with Warfarin: Monitor for increases in INR and prothrombin time (5.2,7).","Acute Tubulointerstitial Nephritis: Discontinue treatment and evaluate patients (5.3).","Clostridium difficile-Associated Diarrhea: PPI therapy may be associated with increased risk of (5.4).","Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for","Severe Cutaneous Adverse Reactions: Discontinue at the first signs or symptoms of severe cutatneous adverse reactions or other signs of hypersensitivity and consider further evaluation (5.6).","Cutaneous and Systemic Lupus Erythematosus: Mostly cutaneous, new onset or exacerbation of existing disease;","Cyanocobalamin (Vitamin B-12) Deficiency: Daily long-term use (e.g., longer than 3 years) may lead to malabsorption","Interaction with Methotrexate: Concomitant use with PPIs may elevate and/or prolong serum concentrations of","Fundic Gland Polyps: Risk increases with long-term use, especially beyond one year. Use the shortest duration of therapy (5.11)."],"specialPopulations":{"Pregnancy":"No information available","Geriatric use":"No information available","Paediatric use":"12 years or above:\n20 mg orally once a day for 8 weeks.\nH. Pylori infection: 1.5 to 2.5 mg/kg/day PO divided twice daily (Max: 20 mg/dose) in combination with amoxicillin and","Renal impairment":"Dose in Renal Impairment GFR (mL/min) | 20-50 | Dose as in normal renal function |\n| --- | --- |\n| 10-20 | Dose as in normal renal function |","Hepatic impairment":"Mild to moderate hepatic impairment: dose adjustment is not be required but starting therapy with lower dose is reasonable. Severe hepatic impairment: Use is contraindicated, however if administered, start with low dose and monitor"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=rabeprazole-40-mg","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:50:18.186849+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:50:24.823471+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:50:18.209024+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rabeprazole-40-mg","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:50:25.660111+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL133572/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:26.544540+00:00"}},"allNames":"rabeprazole 40 mg","offLabel":[],"timeline":[],"aiSummary":"Rabeprazole 40 mg is a small molecule used to evaluate its effects on the pharmacokinetics of other medications, such as nirogacestat, in clinical trials. It has been studied in conditions including gastroesophageal reflux disease and calcium metabolism disorders.","brandName":"Rabeprazole 40 mg","ecosystem":[],"isGeneric":true,"mechanism":{"target":"H+/K+ ATPase","novelty":"Best-in-class","modality":"Small molecule","drugClass":"Proton Pump Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Rabeprazole 40 mg is a substituted benzimidazole that selectively inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells. This results in a decrease in gastric acid secretion, which helps to alleviate symptoms of GERD and other gastrointestinal disorders."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=rabeprazole-40-mg","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=rabeprazole-40-mg","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:28.589659+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Omeprazole","company":"Generic","advantage":"Most cost-effective alternative to rabeprazole, offering similar efficacy for most acid-related conditions at a fraction of the cost"},{"name":"Esomeprazole","company":"Generic","advantage":"Higher potency (20 mg esomeprazole = 32 mg omeprazole) for H. pylori eradication specifically"},{"name":"Rabeprazole","company":"Generic","advantage":"Higher potency (20 mg rabeprazole = 36 mg omeprazole) for H. pylori eradication specifically"},{"name":"Lansoprazole","company":"Generic","advantage":"Cost savings while maintaining efficacy for erosive esophagitis, peptic ulcer disease, and GERD"},{"name":"Famotidine","company":"Generic","advantage":"Cheaper alternative for mild, intermittent acid-related conditions"},{"name":"Ranitidine","company":"Generic","advantage":"Cheaper alternative for mild, intermittent acid-related conditions"}],"genericName":"rabeprazole-40-mg","indications":{"approved":[{"name":"Gastroesophageal Reflux Disease (GERD)","regulator":"FDA"},{"name":"Erosive Esophagitis","regulator":"FDA"},{"name":"Pathological Hypersecretory Conditions","regulator":"FDA"},{"name":"Zollinger-Ellison Syndrome","regulator":"FDA"},{"name":"Erosive Esophagitis in Pediatric Patients 1 to 11 Years Old","regulator":"FDA"},{"name":"Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years Old","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06105983","phase":"PHASE1","title":"A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-11-03","conditions":"Healthy","enrollment":40},{"nctId":"NCT05602597","phase":"PHASE1","title":"HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2022-06-01","conditions":"Relapsed or Refractory Lymphoma","enrollment":59},{"nctId":"NCT04645940","phase":"PHASE1","title":"Fruquintinib Food Effect and Proton Pump Inhibitor Study","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2020-09-24","conditions":"Drug Interaction, Food-drug Interaction","enrollment":14},{"nctId":"NCT04510649","phase":"PHASE1","title":"Surufatinib DDI With a PPI and a CYP3A Inducer","status":"COMPLETED","sponsor":"Hutchison Medipharma Limited","startDate":"2020-07-09","conditions":"Healthy","enrollment":28},{"nctId":"NCT01954043","phase":"PHASE1","title":"A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-12-20","conditions":"Cancer","enrollment":23},{"nctId":"NCT01089543","phase":"PHASE2","title":"A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2010-04","conditions":"Functional Dyspepsia","enrollment":338}],"_emaApprovals":[{"date":"","name":"Rabeprazole 40 mg","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL133572","moleculeType":"Small molecule","molecularWeight":"681.40"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL133572"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":20,"therapeuticAreas":["Gastroenterology"],"biosimilarFilings":[],"recentPublications":[{"date":"2025 Nov 3","pmid":"41060706","title":"Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH.","journal":"Molecular pharmaceutics"},{"date":"2025 Mar","pmid":"40077903","title":"Assessment of Food Effect and pH-Dependent Drug-Drug Interactions of Fruquintinib in Healthy Subjects.","journal":"Clinical and translational science"},{"date":"2019 Aug 15","pmid":"32598752","title":"[Efficacy of H. pylori eradication depending on genetic polymorphism of CYP2C19, MDR1 and IL-1β].","journal":"Terapevticheskii arkhiv"},{"date":"2020 Jul","pmid":"32319196","title":"Proton pump inhibitors enhance intestinal permeability via dysbiosis of gut microbiota under stressed conditions in mice.","journal":"Neurogastroenterology and motility"},{"date":"2018 Mar","pmid":"29593799","title":"Comparison of the efficacy and safety of hybrid and sequential therapies as a first-line regimen for Helicobacter pylori infection in Turkey.","journal":"Archives of medical science : AMS"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:28.589659+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}